Skip to content

Clinical trials

Completed Testicular Neoplasms trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Testicular Neoplasms Status: Completed Country / region: United States Clear all

113 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20008
20015
20026
200310
20049
20054
20066
20077
20083
20093
20101
20114
20131
20141
20152
20162
20171
20181
20201
20211
20232
20242
20252

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed113

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)15
Memorial Sloan Kettering Cancer Center14
Fred Hutchinson Cancer Center13
Children's Oncology Group9
National Institutes of Health Clinical Center (CC)5
Eastern Cooperative Oncology Group3
Wake Forest University Health Sciences3
Abramson Cancer Center at Penn Medicine2
Case Comprehensive Cancer Center2
City of Hope Medical Center2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Testicular Neoplasms113
Breast Neoplasms51
Ovarian Neoplasms43
Neuroblastoma42
Burkitt Lymphoma40
Lymphoma, Non-Hodgkin40
Precursor Cell Lymphoblastic Leukemia-Lymphoma40
Carcinoma, Ovarian Epithelial39
Teratoma38
Hodgkin Disease37

Trials

Showing 1 to 25 of 113. Each trial links to its page on Pharma Observatory.

13 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.